• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 6th July 2011

News Release: Fighting Superbugs

A new report today by the Office of Health Economics (OHE) called for a shake up in the way future antibiotics are to be rewarded in Europe so that biopharmaceutical companies can spend more to fight superbugs. Report recommends new…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
New Drugs to Tackle Antimicrobial Resistance

A new report today by the Office of Health Economics (OHE) called for a shake up in the way future antibiotics are to be rewarded in Europe so that biopharmaceutical companies can spend more to fight superbugs.

Report recommends new ways to boost R & D in fight against superbugs

New Drugs to Tackle Antimicrobial Resistance

A new report today by the Office of Health Economics (OHE) called for a shake up in the way future antibiotics are to be rewarded in Europe so that biopharmaceutical companies can spend more to fight superbugs. The report also calls for more research to better quantify the value of the expected health benefits of investing in antibiotic research and development, and for more dialogue, not only between the EU and the US but, given the global nature of the problem, other institutions as well.

Bacteria have developed resistance to almost every single antibiotic developed in the past 50 years or so – and the rate of resistance to new antibiotics is increasing rapidly, and new superbugs are emerging all the time. Even the strain of E-coli responsible for the current outbreak has been found to be resistant to over 12 antibiotics in eight different classes. The danger of resistant bacteria is that without effective treatment, diseases with traditionally high cure rates, such as pneumonia, become more difficult to treat. And “routine” procedures, such as organ transplants and hip replacement surgery, which rely on antibiotics, may no longer become possible or carry a greater risk of failure.

Compounding the problem is the lack of new antibiotics in the pharmaceutical pipeline. Very few new classes of antibiotics have been discovered in the past decades. The two main reasons for this are the low returns on R&D investment in this area and a restricted use of newer antibiotics to manage resistance.

The OHE makes the following two alternative recommendations at European level on how future antibiotics should be rewarded:

  • First, a hybrid approach whereby EU regulatory authorities need to provide an accelerated review for new antibiotics and Member States should ensure that prices reflect the growing cost of antibiotic resistance. This should be accompanied by restrictions on the use of new antibiotics to delay the build-up of resistance; or
  • Second, companies receive an upfront payment for registration, rather than for volume of use. If correctly designed, this second recommendation is better able to balance the tension between public health goals of policy makers – to slow the growth and spread of resistance and encourage the development of new antibiotics – and the need for pharmaceutical companies to earn a return on their R&D investments.

Adrian Towse, Director of OHE, said “The European Commission has been tasked to come up with a comprehensive action plan with proposals for incentives to develop new antibiotics by the end of this year. It is essential that this happens and that new incentives are introduced to make sure that we get new antibiotics and that their use is managed to prevent superbugs building up resistance”.

Read or download full report

Notes to Editors

Conclusions from the Council of the European Union (December 2009): Three presidencies of the EU have placed a major focus on antibiotic resistance. The Swedish Presidency hosted a conference in September 2009 titled, “Innovative Incentives for Effective Antibacterials”. The outcome of the conference was that the Council of the European Union formally adopted the conclusions of the conference in December 2009. Among the conclusions was a call to the European Commission to come up with a comprehensive action plan with proposals for incentives to develop new antibiotics. They were given until the end of 2011 to develop that action plan.

The Office of Health Economics (OHE) provides independent research, advisory and consultancy services on policy implications and economic issues within the pharmaceutical, health care and biotechnology industries. Its main areas of focus are: the pharmaceutical and biotechnology industry, health care systems-their financing and organisation-and the economics of health technology assessment. Further information on the OHE can be found at OHE’s webpage: www.ohe.org

The OHE has a long-standing involvement in the area of antibiotic resistance and more generally, in the debate about how to encourage R&D in areas where normal market mechanisms have proved inadequate. This report was funded by a grant from GlaxoSmithKline. It is available for download from the OHE website.

Contacts

Professor Adrian Towse, Director
+44 207 747 1407

Priya Sharma, Health Economist
+44 207 747 8860

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation
  • Innovation

Related News

NGS report_AdobeStock_406823942_landscape
  • News
  • July 2023

NGS testing for lung cancer across Europe still limited, despite clear case for adoption

Read more
Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
  • News
  • July 2022

OHE is Leading Research to Develop an EQ-5D ‘Bolt-on’ for Hearing

Read more
  • News
  • October 2021

We have launched OHE Bulletin, a new monthly newsletter

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!